105.      Wood RFM, Thompson JF, Allen NH, Ting A, Morris PJ. The consequences of conversion from cyclosporine to azathioprine and prednisolone in renal allograft recipients. Transplant Proc 1983;15:2862-8.

104.      Wood RFM, Bolton EM, Thompson JF, Morris PJ, Mason DY. Characterisation of cellular infiltrates in renal allografts by fine-needle aspiration - a simple technique using double labelling with monoclonal antibodies. Transplant Proc 1983;15:1847-8.

103.      Thompson JF, Wood RF, Cahill AP, Franklin PM, Morris PJ. Kidney transplantation and seat belt legislation. Br Med J (Clin Res Ed) 1983;287:1260-1.

102.      Thompson JF, Walker CJ. The management of pancreatic carcinoma: a review of 173 cases. Aust N Z J Surg 1983;53:25-30.

101.      Thompson JF, Chalmers DHK, Wood RFM, Morris PJ. Renal allograft monitoring by fine needle aspirtaion cytology. Transplantation and Clinical Immunology 1983;15:207-17.

100.      Thompson JF, Chalmers DH, Wood RF, Kirkham SR, Morris PJ. Sudden death following high-dose intravenous methylprednisolone. Transplantation 1983;36:594-6.

99.       Thompson JF, Chalmers DH, Hunnisett AG, Wood RF, Morris PJ. Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine. Transplantation 1983;36:204-6.

98.       Thompson JF, Chalmers DH, Carter NP, Wood RFM, Morris PJ. Clinical and immunologic effects of conversion to cyclosporin A therapy in long-term renal allograft recipients. Transplant Proc 1983;15:1930-2.

97.       Scheibner A, McCarthy WH, Milton GW, Nordlund JJ. Langerhans cell and melanocyte distribution in "normal" human epidermis. Preliminary report. Australas J Dermatol 1983;24:9-16.

96.       Reddel RR, Thompson JF, Raghavan D, Tattersall MH, Levi JA, Coupland GA, Fox RM, Coates AS, Woods RL, Ng AB. Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy. J Surg Oncol 1983;23:223-7.

95.       Mortimer PS, Thompson JF, Dawber RP, Ryan TJ, Morris PJ. Hypertrichosis and multiple cutaneous squamous cell carcinomas in association with cyclosporin A therapy. J R Soc Med 1983;76:786-7.

94.       Morris PJ, French ME, Dunnill MS, Hunnisett AG, Ting A, Thompson JF, Wood RF. A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983;36:273-7.

93.       McGovern VJ, Shaw HM, Milton GW. Prognostic significance of a polypoid configuration in malignant melanoma. Histopathology 1983;7:663-72.

92.       McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983;7:673-80.

91.       Kourtesis GJ, McCarthy WH, Milton GW. Major amputations for melanoma. Aust N Z J Surg 1983;53:241-4.

90.       Hersey P, Grace J, Murray E, Palmer A, McCarthy WH. Expression of Thy-1 antigen on human melanoma cells. Int J Cancer 1983;32:21-5.

89.       Hersey P, Edwards A, Murray E, McCarthy WH, Milton GW. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients. J Natl Cancer Inst 1983;71:45-53.

88.       Hersey P, Edwards A, Milton GW, McCarthy WH. No evidence for an association between natural killer cell activity and prognosis in melanoma patients. Nat Immun Cell Growth Regul 1983;3:87-94.

87.       Hersey P, Bradley M, Hasic E, Haran G, Edwards A, McCarthy WH. Immunological effects of solarium exposure. Lancet 1983;1:545-8.

86.       Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH. Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol 1983;131:2837-42.

85.       French ME, Thompson JF, Hunnisett AGW, Wood RFM, Morris PJ. Impaired function of renal allografts during treatment with cyclosporin A: nephrotoxicity or rejection? Transplant Proc 1983;15:485-8.

84.       Carter NP, Cullen PR, Thompson JF, Bewick ALT, Wood RFM, Morris PJ. Monitoring lymphocyte subpopulations in renal allograft recipients. Transplant Proc 1983;15:1157-9.

83.       Bolton EM, Thompson JF, Wood RF, Morris PJ. Immunoperoxidase staining of fine-needle aspiration biopsies and needle core biopsies from renal allografts. Transplantation 1983;36:728-31.

82.       Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R, Hersey P. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 1983;47:123-33.

81.       Beral V, Evans S, Shaw H, Milton G. Cutaneous factors related to the risk of malignant melanoma. Br J Dermatol 1983;109:165-72.

80.       Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, McCarthy WH, Murad TM, Maddox WA. Changing trends in cutaneous melanoma over a quarter century in Alabama, USA, and New South Wales, Australia. Cancer 1983;52:1748-53.

79.       Wood RF, Bolton EM, Thompson JF, Morris PJ. Monoclonal antibodies and fine needle aspiration cytology in detecting renal allograft rejection. Lancet 1982;2:278.

78.       Sheil AR, BM H, DJ T, GG D, MS S, JF T, JS H, JR J, J M, JR R, J B. Pre-operative administration of cyclosporin A to cadaveric donor renal allograft recipients (preliminary report from a controlled clinical trial). In: White D, ed. Cyclosporin A. Amsterdam: Elsevier Biomedical Press; 1982:387-92.

77.       Shaw HM, McGovern VJ, Milton GW, Farago GA, McCarthy WH. The female superiority in survival in clinical stage II cutaneous malignant melanoma. Cancer 1982;49:1941-4.

76.       Scheibner A, Milton GW, McCarthy WH, Norlund JJ, Pearson LJ. Multiple primary melanoma - a review of 90 cases. Australas J Dermatol 1982;23:1-8.

75.       Ruell P, Murray E, McCarthy WH, Hersey P. Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma. Oncodev Biol Med 1982;3:1-12.

74.       Morris PJ, Carter NP, Cullen PR, Thompson JF, Wood RF. Role of T-cell-subset monitoring in renal-allograft recipients. N Engl J Med 1982;306:1110-1.

73.       Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong SJ. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982;69:108-11.

72.       McGovern VJ, Shaw HM, Milton GW, McCarthy WH. Ulceration and prognosis in cutaneous malignant melanoma. Histopathology 1982;6:399-407.

71.       McCarthy WH, Dobson AJ, Martyn AL, Roberts G. Melanoma in New South Wales 1970-76: surgical therapy and survival. Aust N Z J Surg 1982;52:424-30.

70.       Hersey P, Hobbs A, Edwards A, McCarthy WH, McGovern VJ. Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 1982;42:363-8.

69.       Beral V, Evans S, Shaw H, Milton G. Malignant melanoma and exposure to fluorescent lighting at work. Lancet 1982;2:290-3.

68.       Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, McCarthy WH, Maddox WA. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982;196:677-84.